

Greater Fluid Retention is Associated with Increased Cardiovascular Mortality in Different Groups of CKD Patients on Hemodialysis

Kamyar Kalantar-Zadeh, MD, MPH, PhD^{1,2}, Deborah L Regidor, PhD^{1,2}; Csaba P Kovcsdy, MD³; Suphamai Bunnapradist, MD²; David Van Wyck, MD⁴; Tamara B Horwich, MD²; and Gregg C Fonarow, MD²

(1) Harold Simmons Center for Kidney Disease Research & Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA, and David Geffen School of Medicine at UCLA, Torrance and Los Angeles, CA; (2) Dept Epidemiology, UCLA School of Public Health, (3) Salem VA Medical Center, Salem, VA; (4) DaVita, Inc, El Segundo, CA;


Background

- Maintenance hemodialysis (MHD) patients retain fluid frequently which may be associated with worse survival in certain subgroups than others.
- We hypothesized that in MHD patients greater interdialytic fluid retention is associated with poor survival.


Methods

- We examined the 2-year (7/2001-6/2003) mortality in 34,003 MHD patients across the United States, who had an average weight gain of at least 0.5 kg above their end-dialysis dry weight by the time the subsequent HD treatment started.
- The 3-month average interdialytic weight gain was dichotomized into two categories of 0.5 to 2.0 kg (reference) and ≥ 2.0 kg.

- After multivariate adjustment for demographics (case-mix) and laboratory surrogates of malnutrition and inflammation, higher weight gain ≥ 2.0 kg was significantly associated with increased death risk in Blacks (death hazard ratio [HD] and 95% confidence interval [CI]: 1.10 [1.01-1.20]) non-diabetics (1.07 [1.01-1.14]) MHD patients with 3 to 6 months on dialysis 1.23 [1.14-1.33] and between 6 months and 2 years 1.20 [1.09-1.33] and those with albumin >3.8 g/dL 1.08 [1.01-1.18] (see Figure).



Results



Conclusions

- In MHD patients greater fluid retention of 2.0 kg or higher between two consecutive HD treatment sessions appears associated with higher death risk among Blacks, non-diabetics, those with less than 2 years of HD treatment, and those with better nutritional status.
- The mechanisms by which fluid retention may influence survival in HD warrants further research.

Acknowledgements

Correspondence:
Kamyar Kalantar-Zadeh, MD, MPH, PhD
Harold Simmons Center for Kidney Disease Research & Epidemiology
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
1124 W. Carson St., C-1 Annex
Torrance, CA 90502-2064
Tel: (310) 222-3891, Fax: (310) 782-1837
Cell: (310) 686-7908
Email Address: kamkal@ucla.edu

Funding Source: Funding Source: Supported by a research grant from DaVita Clinical Research (DCR), and philanthropist Mr. Harold C. Simmons. KKZ has been supported by American Heart Association (AHA) grant 0655776Y and NIH/NIDDK grants R01 DK078106 and R21 DK078012. DCR provided the clinical data for this research project and is committed to advancing the knowledge and practice of kidney care.
Relevant Conflict of Interest: KKZ has received grants and/or honoraria from Abbott (the manufacturer of ZemplarTM), Amgen (manufacturer of seniparTM) and Genzyme (manufacturer of SevelamerTM and HecoxalTM) and Shire (manufacturer of FosrenonTM).

Disclosures: Abstract Poster Sessions, Session Number: APS29.2, Session Title: Heart Failure: Nutritional History, Biomarkers and Prognosis, Session Date: Sunday, November 09, 2008, 9:00 am - 5:00 pm, Location: Hall A - B1